Novo Nordisk concludes USD 4.7 billion acquisition of Akero Therapeutics We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Novo Nordisk to acquire Akero Therapeutics for up to USD 5.2 billion We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to add MASH to the label of its GLP-1 agonist semaglutide. The Danish pharma group is paying $54 per share in cash for Akero, with another $6 per share…